Literature DB >> 16421740

Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies.

Hiroshige Fujishiro1, Hiroyuki Umegaki, Daisuke Isojima, Hiroyasu Akatsu, Akihisa Iguchi, Kenji Kosaka.   

Abstract

The cholinergic basal forebrain is divided into four subregions (Ch1-4), and cholinergic neuronal loss in the nucleus basalis of Meynert (Ch4) has been correlated with cognitive impairments in both Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). However, the Ch1-2 regions, which provide the major cholinergic innervation to the hippocampus, have not been investigated in DLB. The purpose of this study was to reveal the cholinergic neuronal changes in the medial septum (Ch1) and the nucleus of the vertical limb of the diagonal band (Ch2) of DLB brains. Using choline acetyltransferase (ChAT) immunohistochemistry, we showed that the number of ChAT-immunoreactive neurons in DLB brains was significantly lower than the numbers in AD and non-demented (control) brains. No significant difference in the number of ChAT-immunoreactive neurons was found between the AD and control brains. Moreover, the size of the ChAT-immunoreactive neurons was significantly smaller in the AD and DLB brains than in the control brains. These results show that cholinergic neurons of the Ch1-2 regions are more severely affected in DLB than in AD. Our DLB cases did not fulfill the neuropathologic criteria for definite AD. Furthermore, some Lewy bodies were observed in the Ch1-2 regions. Thus, cholinergic neuronal loss in the Ch1-2 regions might be specific to the pathology of DLB. Taking the distribution of cholinergic fibers in the hippocampus into consideration, this study suggests a possibility that hippocampal cholinergic projection is involved in Lewy-related neurites in the CA2-3 regions, the origin of which remains unclear.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421740     DOI: 10.1007/s00401-005-0004-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  18 in total

1.  Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study.

Authors:  Ingo Kilimann; Michel Grothe; Helmut Heinsen; Eduardo Joaquim Lopez Alho; Lea Grinberg; Edson Amaro; Gláucia Aparecida Bento Dos Santos; Rafael Emídio da Silva; Alex J Mitchell; Giovanni B Frisoni; Arun L W Bokde; Andreas Fellgiebel; Massimo Filippi; Harald Hampel; Stefan Klöppel; Stefan J Teipel
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies.

Authors:  Berneet Kaur; Danielle J Harvey; Charles S Decarli; Lin Zhang; Marwan N Sabbagh; John M Olichney
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

3.  Metabolic connectomics targeting brain pathology in dementia with Lewy bodies.

Authors:  Silvia P Caminiti; Marco Tettamanti; Arianna Sala; Luca Presotto; Sandro Iannaccone; Stefano F Cappa; Giuseppe Magnani; Daniela Perani
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack
Journal:  Brain       Date:  2007-01-31       Impact factor: 13.501

Review 5.  Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances.

Authors:  Marian Tsanov
Journal:  Front Neural Circuits       Date:  2022-05-31       Impact factor: 3.342

6.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.

Authors:  Michel J Grothe; Christina Schuster; Florian Bauer; Helmut Heinsen; Johannes Prudlo; Stefan J Teipel
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

7.  TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

Authors:  Yuu Sako; Emi Kurimoto; Takao Mandai; Atsushi Suzuki; Maiko Tanaka; Motohisa Suzuki; Yuji Shimizu; Masami Yamada; Haruhide Kimura
Journal:  Neuropsychopharmacology       Date:  2018-08-01       Impact factor: 7.853

Review 8.  Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease.

Authors:  Alan King Lun Liu; Raymond Chuen-Chung Chang; Ronald K B Pearce; Steve M Gentleman
Journal:  Acta Neuropathol       Date:  2015-01-30       Impact factor: 17.088

9.  Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia: A Phase I Randomized Clinical Trial.

Authors:  David Maltête; David Wallon; Julie Bourilhon; Romain Lefaucheur; Teodor Danaila; Stéphane Thobois; Luc Defebvre; Kathy Dujardin; Jean-Luc Houeto; Olivier Godefroy; Pierre Krystkowiak; Olivier Martinaud; André Gillibert; Mathieu Chastan; Pierre Vera; Didier Hannequin; Marie-Laure Welter; Stéphane Derrey
Journal:  Neurology       Date:  2020-11-16       Impact factor: 9.910

Review 10.  Vascular dementia and the cholinergic pathways.

Authors:  Eliasz Engelhardt; Denise Madeira Moreira; Jerson Laks
Journal:  Dement Neuropsychol       Date:  2007 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.